Skip to main content
    M

    MAIA Biotechnology Inc. (MAIA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.14
    +0.02 (+1.79%)

    Market Cap: $70.69M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(11/16)
    Avg Surprise
    +6.93%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.13
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.12-8.3%
    60d ago$-0.12-8.3%
    30d ago$-0.12-8.3%
    7d ago$-0.12-8.3%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.12 - $-0.12
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 10
    		$-0.13$-0.11-18.18%Miss+27.8%
    Mar 26
    Reported May 11
    		$-0.14$-0.18+22.22%Beat+12.5%
    Dec 25
    Reported Mar 23
    		$-0.14$-0.13-5.23%Miss+57.3%
    Sep 25
    Reported Nov 7
    		$-0.27$-0.19-42.11%Miss-145.5%
    Jun 25
    Reported Aug 11
    		$-0.18$-0.25+28.00%Beat+55.0%
    Mar 25
    Reported May 9
    		$-0.16$-0.18+11.11%Beat+65.2%
    Dec 24
    Reported Mar 21
    		$-0.32$-0.35+8.57%Beat+20.0%
    Sep 24
    Reported Nov 12
    		$-0.11N/A+76.60%Beat+69.4%
    Jun 24
    Reported Aug 9
    		$-0.40$-0.41+2.44%Beat-14.3%
    Mar 24
    Reported May 14
    		$-0.46$-0.39-17.95%Miss-21.1%
    Dec 23
    Reported Mar 21
    		$-0.40$-0.39-2.56%Miss-14.3%
    Sep 23
    Reported Nov 7
    		$-0.36$-0.38+5.26%Beat+26.5%
    Jun 23
    Reported Aug 8
    		$-0.35$-0.43+18.60%Beat-400.0%
    Mar 23
    Reported May 8
    		$-0.38$-0.42+9.52%Beat+62.7%
    Dec 22
    Reported Mar 24
    		$-0.35$-0.41+14.63%Beat-
    Sep 22
    Reported Nov 9
    		$-0.49$-0.49+0.00%Beat-
    Jun 22
    Reported Aug 8
    		$-0.07$0.00N/AMiss-
    Sep 21
    Reported Dec 22
    		$-1.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.68EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-218.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.51xQuick Ratio4.51x
    Trading Statistics
    Beta0.28Avg Volume609.96K
    52-Week High$3.1952-Week Low$0.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.17
    SMA 20$1.21
    SMA 50$1.30
    SMA 200$1.48
    EMA 10$1.17
    EMA 20$1.21
    EMA 50$1.27
    EMA 200$1.39

    MACD

    Line: -0.05Signal: -0.04Hist: -0.00

    ADX

    ADX: 13.5+DI: 16.2-DI: 22.0

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down96.0
    PSAR$1.23

    Bollinger Bands

    Upper Band$1.35
    Lower Band$1.07
    %B Position2321%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    39.5

    Momentum Oscillators

    Stoch %K16.0
    Stoch %D18.6
    Williams %R-75.7
    ROC (10d)-2.6%
    Momentum-0.03
    CCI (20d)-96.0
    MFI (14d)38.9

    Volatility Measures

    ATR (14d)$0.06(5.5%)
    StdDev (20d)0.07
    Hist Vol49.5%(High)

    Volume Flow

    VWAP$1.13
    OBV49.0M
    AD Line-21.4M
    CMF (20d)-0.291

    Volume Metrics

    Avg Vol (20d)593.1K
    Vol Ratio0.5x(Low)
    VWMA (20d)$1.22

    Pivot Points

    R3$1.21
    R2$1.19
    R1$1.15
    Pivot Point$1.13
    S1$1.09
    S2$1.07
    S3$1.03

    Advanced Oscillators

    TSI-20.26
    Ultimate Osc43.5
    KST-125.63

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$8.32M$6.95M$4.32M$9.36M$5.17M$5.43M$5.02M$4.19M$3.80M$3.95M$6.49M$4.90M
    R&D$5.64M$3.53M$1.88M$6.36M$3.11M$3.20M$2.99M$2.67M$2.03M$2.32M$3.83M$2.54M
    SG&A$2.68M$3.42M$2.44M$3.00M$2.06M$2.23M$2.04M$1.52M$1.76M$1.63M$2.66M$2.36M
    Operating Income$-8,317,251$-6,949,929$-4,317,271$-9,360,926$-5,166,058$-5,425,431$-5,004,604$-4,188,468$-3,815,262$-3,948,876$-6,377,842$-4,955,643
    Interest Income$207,173$213,565$0$0$0$0$0$0$88,383$44,118$30,722$3,260
    Interest Expense$0$0$0$0$180,905$0$0$0$5.08M$4.12M$0$1
    Income Before Tax$-7,943,587$-6,369,652$-3,628,761$-8,903,189$-5,346,963$-4,517,259$-3,553,890$-2,735,987$-8,897,324$-8,067,455$-6,216,896$-4,875,743
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,943,587$-6,369,652$-3,628,761$-8,903,189$-5,346,963$-4,517,259$-3,571,938$-2,735,987$-8,879,276$-8,067,455$-6,256,662$-4,875,743
    EBITDA$-8,150,760$-6,583,217$-3,828,231$-8,903,189$-5,346,963$-4,517,259$-3,408,465$-2,735,902$-8,985,707$-8,111,573$-6,137,927$-4,937,450
    EBIT$-8,150,760$-6,583,217$-3,828,231$-8,903,189$-5,346,963$-4,517,259$-3,408,465$-2,735,902$-8,985,707$-8,111,573$-6,137,927$-4,937,450
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MAIA

    News

    MAIA Phase 3 lung cancer trial reaches 65% of target | MAIA Stock News

    MAIA Biotechnology has achieved significant patient enrollment milestones in its Phase 2 THIO-101 and pivotal Phase 3 THIO-104 clinical trials for non-small cell lung cancer...

    Stock Titan•10/7/26•Bullish

    MAIA Biotechnology, Inc. SEC Filing (Oct 7, 2026)

    MAIA Biotechnology, Inc. announced an SEC filing with a neutral impact and sentiment regarding an EFFECT filing. The filing, dated October 7, 2026, pertains to a Notice of Effectiveness for Form S-3...

    Stock Titan•10/7/26•Neutral

    MAIA Biotechnology Releases New Investor Presentation and Update

    MAIA Biotechnology, Inc. (MAIA) has released a new investor presentation and operational summary on its website as of October 6...

    The Globe and Mail•10/7/26•Neutral

    Form 4 Maia Biotechnology Inc For: 7 October By Investing.com

    This article reports on a Form 4 filing for Maia Biotechnology Inc. on October 7, 2026. The financial market news site Investing.com published the information...

    Investing.com Nigeria•10/7/26•Neutral

    MAIA Biotechnology Announces Completion of THIO-101 Phase 2 Enrollment and Reaches 65% of THIO-104 Phase 3 Target

    MAIA Biotechnology has completed enrollment for Part C of its Phase 2 THIO-101 study and achieved 65% of the target enrollment for its pivotal Phase 3 THIO-104 trial...

    Quiver Quantitative•10/7/26•Bullish

    MAIA Valuation and Fair Value

    P/E
    -1.7x
    P/B
    3.4x
    See GNG's fair value

    MAIA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -218.7%

    MAIA Competitors

    CompanyTicker
    Outset Medical IncOM
    Oncolytics Biotech IncONCY
    OKYO Pharma LimitedOKYO
    Coeptis Therapeutics IncCOEP
    ProMIS Neurosciences Inc.PMN
    Fortress Biotech IncFBIO
    LENSAR IncLNSR
    Heron TherapeutiHRTX

    Sector: Healthcare

    MAIA Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    10.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About MAIA

    Does MAIA pay dividends?

    MAIA Biotechnology Inc. (MAIA) does not currently pay a regular dividend.

    What is MAIA's market cap?

    MAIA Biotechnology Inc. (MAIA) has a market capitalization of $70.69M with a current stock price of $1.14.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In